In the second week of the landmark trial between Elon Musk and OpenAI, Musk’s motivations for bringing the suit were under scrutiny. Last week, Musk took the stand, alleging that OpenAI CEO Sam Altman and president Greg Brockman had deceived him into donating $38 million to the company. He claimed that they’d promised to maintain…
The device is being developed by the company’s Devices and Services division, and it would feature personalized features aimed at making it easier to use Amazon’s suite of apps, including Amazon shopping, Prime Video, and Prime Music, according to Reuters.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. OpenAI is throwing everything into building a fully automated researcher OpenAI has a new grand challenge: building an AI researcher—a fully automated agent-based system capable of tackling large, complex problems by…
OpenAI is refocusing its research efforts and throwing its resources into a new grand challenge. The San Francisco firm has set its sights on building what it calls an AI researcher, a fully automated agent-based system that will be able to go off and tackle large, complex problems by itself. OpenAI says that the new…
This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin—which is found in magic mushrooms—are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over…